← Leaderboards
Jack Bergman
Mc Lean Hospital (Belmont, Ma)
$14,885,552
Attributed
$22,149,294
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,149,294 · 11
By mechanism
R01$21,740,829 · 10
U19$408,465 · 1
Top collaborators
- Roger D Spealman11 shared
- Brian D. Kangas6 shared
- Stephen John Kohut6 shared
- Alexandros Makriyannis6 shared
- Sarah L Withey4 shared
- Carol A Paronis3 shared
Most similar at Mc Lean Hospital (Belmont, Ma)
Same institution · by research overlap
- Anna-Liisa Brownell$14,412,968
- Martin H Teicher$21,214,258
- Sydney Archer$408,465
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDoseNonhuman PrimateBaseStimulusResponseMonkeysBehavioralSelf AdministrationChronicAgonistRegimenAddictionRelapseBehaviorPre-ClinicalLigandsProgramsDrug Seeking BehaviorReinforcerDesignCocaineProceduresAttenuated
Grant awards (49)
Neural and Behavioral Consequences of Chronic THC Exposure During Adolescence$1,179,649
R01 · FY2025 · DA · contact PI
Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman Primates$556,272
R01 · FY2023 · DA · contact PI
Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman Primates$718,402
R01 · FY2022 · DA · contact PI
Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman Primates$719,019
R01 · FY2021 · DA · contact PI
In vivo characterization of opioid biased agonists$245,568
R01 · FY2021 · DA
Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman Primates$710,343
R01 · FY2020 · DA · contact PI
In vivo characterization of opioid biased agonists$245,568
R01 · FY2020 · DA
Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman Primates$601,606
R01 · FY2019 · DA · contact PI
In vivo characterization of opioid biased agonists$317,840
R01 · FY2019 · DA
Buprenorphine_A Behavioral Analysis$492,018
R01 · FY2018 · DA · contact PI
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$445,211
R01 · FY2018 · DA · contact PI
Buprenorphine_A Behavioral Analysis$492,018
R01 · FY2017 · DA · contact PI
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$443,481
R01 · FY2017 · DA · contact PI
Buprenorphine_A Behavioral Analysis$510,205
R01 · FY2016 · DA · contact PI
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$429,512
R01 · FY2016 · DA · contact PI
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$423,362
R01 · FY2016 · DA · contact PI
Buprenorphine_A Behavioral Analysis$507,630
R01 · FY2015 · DA · contact PI
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$473,885
R01 · FY2015 · DA · contact PI
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$417,078
R01 · FY2015 · DA · contact PI
Pharmacologic Approaches to Prescription Opioid Addiction and Relapse Prevention$528,330
R01 · FY2014 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$524,102
R01 · FY2014 · DA · contact PI
Buprenorphine_A Behavioral Analysis$492,018
R01 · FY2014 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$529,932
R01 · FY2013 · DA · contact PI
Preclinical Evaluation of Medications to Treat Polydrug Addiction$523,748
R01 · FY2013 · DA · contact PI
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$402,588
R01 · FY2013 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$564,664
R01 · FY2012 · DA · contact PI
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$415,374
R01 · FY2012 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$551,624
R01 · FY2011 · DA · contact PI
Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse$440,311
R01 · FY2011 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$20,520
R01 · FY2011 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$577,205
R01 · FY2010 · DA · contact PI
CB-1 Antagonists for Cannabis Addiction$466,102
R01 · FY2008 · DA · contact PI
CB-1 Antagonists for Cannabis Addiction$461,674
R01 · FY2007 · DA · contact PI
Behavioral Effects and Abuse of Dopaminergic Drugs$337,079
R01 · FY2007 · DA · contact PI
CB-1 Antagonists for Cannabis Addiction$458,043
R01 · FY2006 · DA · contact PI
Cocaine Addiction:Medication Strategies and Evalution$385,718
R01 · FY2006 · DA · contact PI
Behavioral Effects and Abuse of Dopaminergic Drugs$347,147
R01 · FY2006 · DA · contact PI
CB-1 Antagonists for Cannabis Addiction$395,049
R01 · FY2005 · DA
Cocaine Addiction:Medication Strategies and Evalution$395,000
R01 · FY2005 · DA
Behavioral Effects and Abuse of Dopaminergic Drugs$355,500
R01 · FY2005 · DA
CB-1 Antagonists for Cannabis Addiction$61,279
R01 · FY2005 · DA
CB-1 Antagonists for Cannabis Addiction$398,796
R01 · FY2004 · DA
Cocaine Addiction:Medication Strategies and Evalution$395,000
R01 · FY2004 · DA
Behavioral Effects and Abuse of Dopaminergic Drugs$355,500
R01 · FY2004 · DA
Cocaine Addiction:Medication Strategies and Evalution$395,000
R01 · FY2003 · DA
Behavioral Effects and Abuse of Dopaminergic Drugs$355,500
R01 · FY2003 · DA
Cocaine Addiction:Medication Strategies and Evalution$395,000
R01 · FY2002 · DA
BEHAVIORAL PHARMACOLOGY$408,465
U19 · FY2000 · DA
MEDICATIONS FOR COCAINE ABUSE--STRATEGY AND EVALUATION$284,359
R01 · FY2000 · DA